Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis

J Med Chem. 2009 May 14;52(9):3116-20. doi: 10.1021/jm9003126.

Abstract

The Rv3273 gene product of Mycobacterium tuberculosis, a beta-carbonic anhydrase (CA, EC 4.2.1.1), mtCA 3, shows appreciable catalytic activity for CO(2) hydration (k(cat) of 4.3 x 10(5) s(-1), and k(cat)/K(m) of 4.0 x 10(7) M(-1) x s(-1)). A series of sulfonamides/sulfamates was assayed for their interaction with mtCA 3. Sulfanilyl-sulfonamides, acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, benzolamide, and zonisamide, showed effective, submicromolar inhibition (K(I)s of 104-611 nM), the best inhibitor being 2-amino-pyrimidin-4-yl-sulfanilamide (K(I) of 91 nM).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Biocatalysis
  • Carbonic Anhydrase Inhibitors / pharmacology*
  • Carbonic Anhydrases / chemistry
  • Carbonic Anhydrases / genetics*
  • Carbonic Anhydrases / metabolism*
  • Cloning, Molecular
  • Molecular Sequence Data
  • Mycobacterium tuberculosis / enzymology*
  • Sulfonamides / pharmacology
  • Sulfonic Acids / pharmacology

Substances

  • Carbonic Anhydrase Inhibitors
  • Sulfonamides
  • Sulfonic Acids
  • sulfamic acid
  • Carbonic Anhydrases